乳腺癌(BC)患者的高死亡率通常是由于对全身治疗具有抗性的转移。BC患者全身治疗抵抗的两个原因是循环miRNA-221和miR-222,导致BC细胞增殖改善。生存,减少细胞凋亡。这项研究调查了与癌细胞对他莫昔芬治疗的抗性相关的miRNA表达变化,并有望在为表达它们的腔型BC患者提供内分泌治疗之前具有临床意义。
这项病例对照研究包括接受他莫昔芬药物治疗约一年的BC腔亚型患者。此外,病例组有15例局部复发或转移,对照组为19例患者,无局部复发或转移。使用转录物特异性引物用实时PCR进行血浆miR-221/222定量。
■发现病例和对照组之间的循环miR-221表达存在显着差异(P=0.005),但miR-222表达没有显着差异(P=0.070)。miR-221/222表达之间无显著差异,孕激素受体,Ki67蛋白水平,淋巴管浸润,和舞台。然而,受试者操作特征曲线分析显示miR-221/222表达预测他莫昔芬耐药(P=0.030),敏感性为60.00,特异性为83.33%.
■使用循环miR-221/222表达可以预测BC患者的复发以及对他莫昔芬治疗的抗性,和他们的测试是建议的管腔亚型BC患者将接受他莫昔芬治疗,以确定他们的早期他莫昔芬耐药的风险,提高治疗效果。
The high mortality rate in breast cancer (BC) patients is generally due to metastases resistant to systemic therapy. Two causes of systemic therapy resistance in BC patients are circulating miRNAs-221 and miR-222, leading to improved BC cell proliferation, survival, and reduced cell apoptosis. This study investigated the miRNA expression changes associated with cancer cell resistance to tamoxifen therapy and is expected to be clinically meaningful before providing endocrine therapy to
luminal-type BC patients who express them.
UNASSIGNED: This
case-control research included individuals with the
luminal subtype of BC who had received tamoxifen medication for around one year. Furthermore, the
case group contained 15 individuals with local recurrence or metastases, while the control group comprised 19 patients without local recurrence or metastases. Plasma miR-221/222 quantification was performed with real-time PCR using transcript-specific primers.
UNASSIGNED: A significant difference was found in circulating miR-221 expression between cases and controls (P=0.005) but not in miR-222 expression (P=0.070). There were no significant differences between miR-221/222 expression, progesterone receptor, Ki67 protein levels, lymphovascular invasion, and stage. However, receiver operator characteristic curve analyses showed miR-221/222 expressions predictive of tamoxifen resistance (P=0.030) with a sensitivity of 60.00 and a specificity of 83.33%.
UNASSIGNED: The use of circulating miR-221/222 expression can predict relapse as well as resistance to tamoxifen treatment in BC patients, and their testing is recommended for
luminal subtype BC patients who will undergo tamoxifen therapy to determine their risk of tamoxifen resistance early, increasing treatment effectiveness.